Actelion is granted Marketing Authorisation for Opsumit (macitentan) in Pulmonary Arterial Hypertension (PAH) by the European Commission
Actelion Pharmaceuticals Ltd /
Actelion is granted Marketing Authorisation for Opsumit (macitentan) in
Pulmonary Arterial Hypertension (PAH) by the European Commission
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* Approval granted by European Commission on 20 December 2013
* Opsumit approved as monotherapy or in combination with another PAH therapy
for the long-term treatment of WHO Functional Class II to III PAH patients
* First EU launch planned in Germany in February 2014
ALLSCHWIL, SWITZERLAND - 20 December 2013 - Actelion Ltd (SIX: ATLN) today
announced that Opsumit(Â®) (macitentan), a novel dual endothelin receptor
antagonist (ERA), has been granted marketing authorisation for the long-term
treatment of PAH in the EU by the European Commission. Opsumit, as monotherapy
or in combination, is indicated for the longterm treatment of pulmonary arterial
hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.
Efficacy has been shown in a PAH population including idiopathic and heritable
PAH, PAH associated with connective tissue disorders, and PAH associated with
corrected simple congenital heart disease.
Macitentan 10mg is also described as reducing the risk of PAH related death or
hospitalization for PAH up to end of treatment (EOT) by 50% (HR 0.50; 97.5% CI:
0.34 to 0.75; logrank p < 0.0001). Macitentan 10mg improved quality of life
assessed by the SF-36 questionnaire.
Dr Nazzareno GaliÃ¨ from the Institute of Cardiology, University of Bologna,
Bologna, Italy spoke of the impact of the availability of Opsumit, "We are all
very pleased with the approval of Opsumit in Europe. For the first time we can
offer patients a therapy that has demonstrated improvement in long term clinical
outcome showing a significant effect in naive patients and patients who are
already on a specific PAH treatment."
The EU label was based in part on data from the landmark Phase III SERAPHIN
study which was published in the New England Journal of Medicine in August
2013, the SERAPHIN study demonstrated that treatment with macitentan 10 mg
resulted in a 45% risk reduction (hazard ratio [HR] 0.55; 97.5% CI: 0.39 to
0.76; p < 0.0001) of the composite morbidity-mortality endpoint up to (EOT) when
compared to placebo.
Jean-Paul Clozel, M.D. and Chief Executive Officer of Actelion commented: "We
are delighted with today's announcement as we believe that Opsumit represents a
major step forward for the management of PAH. Our company strategy of sustaining
and growing our PAH franchise has yet again been bolstered by this approval.
This achievement marks a significant moment for the PAH community in Europe as
the first and only PAH treatment with proven long-term efficacy, from controlled
clinical trials in PAH, and will now offer hope of a better future to those
living with this disease. Actelion is now working to make this important
medicine available to patients around European markets in the coming months."
The most commonly reported adverse drug reactions are nasopharyngitis (14.0%),
headache (13.6%) and anaemia (13.2%). The majority of adverse reactions are mild
to moderate in intensity.
Opsumit was approved by the FDA on 18 October 2013 and by Health Canada in
NovemberÂ 2013. It is also undergoing regulatory assessment in other countries
NOTES TO THE EDITOR
ABOUT OPSUMIT(Â®) (MACITENTAN)
Opsumit (macitentan) is a novel dual endothelin receptor antagonist (ERA) that
resulted from a tailored drug discovery process with the target of developing an
ERA to address efficacy and safety [2,3].
ABOUT THE SERAPHIN STUDY
SERAPHIN (Study with an Endothelin Receptor Antagonist in Pulmonary arterial
Hypertension to Improve cliNical outcome) was the largest and longest
randomized, controlled study in PAH patients to include a clearly defined
morbidity/mortality primary endpoint . The pivotal Phase III study was
designed to evaluate the efficacy and safety of Opsumit (macitentan) - a novel
dual endothelin receptor antagonist that resulted from a tailored drug discovery
process - through the primary endpoint of time to first morbidity and all-cause
mortality event in patients with symptomatic PAH.
Global enrolment was completed in December 2009 with a total of 742 patients.
Patients were randomized 1:1:1 to receive two different doses of macitentan (3
mg and 10 mg once daily) or placebo. Patients were allowed to receive PAH
background therapy throughout the study, either PDE-5 inhibitors or oral/inhaled
prostanoids. This event-driven study was conducted in 151 centers from almost
40 countries in North America, Latin America, Europe, Asia-Pacific and Africa
and was completed in the first half of 2012, with 287 patients having an
ABOUT SERAPHIN STUDY DATA
Patients were randomized to placebo (n=250), macitentan 3 mg (n=250), or
macitentan 10 mg (n=242). The primary end point occurred in 46.4%, 38.0%, and
31.4% of the patients in these groups, respectively. The hazard ratio for
macitentan 3 mg versus placebo was 0.70 (97.5% CI, 0.52 to 0.96; p=0.0108) and
the hazard ratio for macitentan 10 mg versus placebo was 0.55 (97.5% CI, 0.39 to
0.76; p<0.0001). Worsening of pulmonary arterial hypertension was the most
frequent primary end point event. The effect of macitentan on this end point was
observed irrespective of background therapy for pulmonary arterial hypertension.
ABOUT THE SAFETY AND TOLERABILITY PROFILE
The most commonly reported adverse drug reactions with Opsumit are
nasopharyngitis (14.0%), headache (13.6%) and anaemia (13.2%). The majority of
adverse reactions are mild to moderate in intensity.
ABOUT OPSUMIT (MACITENTAN) SUBMISSIONS TO HEALTHCARE AUTHORITIES
Approval of the new drug application for Opsumit (macitentan) was issued by the
US Food and Drug Administration (FDA) on 18 October 2013 for the treatment of
pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression.
Disease progression included: death, initiation of intravenous (IV) or
subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk
distance, worsened PAH symptoms and need for additional PAH treatment). Opsumit
also reduced hospitalization for PAH.
Health Canada approved Opsumit for the long-term treatment of pulmonary arterial
hypertension (PAH, WHO Group l) to reduce morbidity in patients of WHO
Functional Class II or III whose PAH is either idiopathic or heritable, or
associated with connective tissue disease or congenital heart disease in
Regulatory reviews are ongoing in Switzerland, Australia, Taiwan, Mexico, Korea
ABOUT PULMONARY ARTERIAL HYPERTENSION [4, 5]
Pulmonary arterial hypertension (PAH) is a chronic, life-threatening disorder
characterized by abnormally high blood pressure in the arteries between the
heart and lungs of an affected individual. The symptoms of PAH are non-specific
and can range from mild breathlessness and fatigue during normal daily activity
to symptoms of right heart failure and severe restrictions on exercise capacity
and ultimately reduced life expectancy.
PAH is one group within the classification of pulmonary hypertension (PH). This
group includes idiopathic PAH, heritable PAH and PAH caused by factors which
include connective tissue disease, HIV infection and congenital heart disease.
The last decade has seen significant advances in the understanding of the
pathophysiology of PAH, which has been paralleled with developments of treatment
guidelines and new therapies. Drugs targeting the three pathways that have been
established in the pathogenesis of PAH are endothelin receptor antagonists
(ERAs), prostacyclins and phosphodiesterase-5 inhibitors. PAH treatments have
transformed the prognosis for PAH patients from symptomatic improvements in
exercise tolerance 10 years ago to delayed disease progression today. Improved
disease awareness and evidence-based guidelines developed from randomized
controlled clinical trial data have highlighted the need for early intervention,
goal-oriented treatment and combination therapy.
In PAH, survival rates are unacceptably low and PAH remains incurable.
1. Pulido TÂ et al.Â Macitentan and Morbidity and Mortality in Pulmonary Arterial
Hypertension.Â NÂ Engl J MedÂ 2013;369:809-18.
2. Bolli MH et al. The Discovery of N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-
pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an
Orally Active, Potent Dual Endothelin Receptor Antagonist. J Med Chem.
3. Iglarz M. et al. Pharmacology of macitentan, an orally active tissue
targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther.
4. Proceedings of the 4th world symposium on pulmonary hypertension. J Am
CollCardiol 2009;54(1 Suppl).
5. GaliÃ¨ N, Hoeper MM, Humbert M, et al; ESC Committee for Practice Guidelines
(CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension:
the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of
the European Society of Cardiology (ESC) and the European Respiratory
Society (ERS), endorsed by the International Society of Heart and Lung
Transplantation (ISHLT). Eur Heart J 2009;30:2493-537.
6. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An
evaluation of long-term survival from time of diagnosis in pulmonary
arterial hypertension from REVEAL. Chest 2012;142:448-56.
Actelion Ltd. is a leading biopharmaceutical company focused on the discovery,
development and commercialization of innovative drugs for diseases with
significant unmet medical needs.
Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our
portfolio of PAH treatments covers the entire spectrum of care, from WHO
Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous
medications.Â Actelion is also offering treatments for a number of specialist
diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital
Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides in
patients with cutaneous T-cell lymphoma.
Founded in late 1997, with now over 2,400 dedicated professionals covering all
key markets around the worldÂ including the US, Japan, China, Russia and Mexico,
Actelion has its corporate headquarters in Allschwil / Basel, Switzerland.
Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as
part of the Swiss blue-chip index SMI (Swiss Market Index SMIÂ®). All trademarks
are legally protected.
For further information please contact:
Senior Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
The above information contains certain "forward-looking statements", relating to
the company's business, which can be identified by the use of forward-looking
terminology such as "estimates",Â "believes", "expects", "may", "are expected
to", "will", "will continue", "should", "would be", "seeks",Â "pending" or
"anticipates" or similar expressions, or by discussions of strategy, plans or
intentions.Â Such statements include descriptions of the company's investment
and research and development programs and anticipated expenditures in connection
therewith, descriptions of new products expected to be introduced by the company
and anticipated customer demand for such products and products in the company's
existing portfolio. Such statements reflect the current views of the company
with respect to future events and are subject to certain risks, uncertainties
and assumptions. Many factors could cause the actual results, performance or
achievements of the company to be materially different from any future results,
performances or achievements that may be expressed or implied by such forward-
looking statements. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those described herein as anticipated, believed,
estimated or expected.
Press Release PDF:
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via GlobeNewswire